Maxim Group Reiterates Sell on Momenta (MNTA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Momenta Phama (MNTA) Resumes Enrollment in M402 Combo Phase 2
December 21, 2015 8:04 AM ESTMomenta Pharmaceuticals, Inc. (NASDAQ: MNTA) announced that it has resumed patient enrollment in its ongoing Phase 2 portion of the trial A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with nab-Paclitaxel and Gemcitabine in Patients with Metastatic... More
Momenta Phama (MNTA), Baxalta (BXLT) ANnounce M923 Met Primary Endpoint vs. HUMIRA
December 21, 2015 6:47 AM ESTBaxalta Incorporated (NYSE: BXLT) and Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), announced that M923 met the primary endpoint in a randomized, double-blind, three-arm, parallel group, single-dose study. The primary objective of the study was to evaluate the pharmacokinetics of M923 compared to both U.S. and EU sourced HUMIRA® reference products.
We are encouraged by the results of this study, said John Orloff, M.D., head of Research &... More
